Small‐molecule inhibitors for the HSP90 have been extensively exploited in preclinical studies representing promising agents in cancer treatment and some of them, such as tanespimycin (17AAG) and ganetespib (STA9090), are in phase II/III clinical studies in cancers patients alone or in combination with conventional chemotherapy2. Here, HSP90AB1 is linked to cancer.